Aadi Bioscience : Corporate Presentation

Forward-Looking Statements

Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. Forward- looking statements may include, without limitation, statements regarding: the anticipated timing of commencement, enrollment and completion of clinical trials of Aadi Bioscience, Inc. ("Aadi"); the anticipated timing for releasing data for Aadi's clinical trials, including the PRECISION1, neuroendocrine tumors (NETs) and endometrioid-type endometrial cancer (EEC); Aadi's anticipated cash runway extending into the fourth quarter of 2025; Aadi's potential to become a leading precision oncology company; and projected annual incidence of cancers with TSC1 and TSC2 alterations and in NETs and EEC and related market opportunities. No forward- looking statement can be guaranteed, and actual results may differ materially from those projected. Aadi uses words such as "anticipates," "believes," "plans," "expects," "projects," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "opportunity," and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Aadi's plans to develop and commercialize FYARRO® (nab-sirolimus,ABI-009); Aadi's commercialization, marketing and manufacturing capabilities and strategy; the clinical utility, potential benefits and market acceptance of FYARRO; risks related to the sufficiency Aadi's cash balance to fund operations; the timing of Aadi's clinical trials, including the timing of the availability of data from such clinical trials; uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications, including potential delays in the commencement, enrollment and completion of such clinical trials; Aadi's plans to research, develop and commercialize its current and future product candidates; Aadi's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to market size, Aadi's competitors and its industry; Aadi's ability to protect its intellectual property position; risks related to the release of interim, topline and preliminary data from clinical trials; and Aadi's estimates regarding future revenue, expenses, capital requirements and need for additional financing.

These risks are described in detail under the caption "Risk Factors" in Aadi's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and other documents filed from time to time with the SEC. Forward-looking statements included in this presentation are based on information available to Aadi as of the date of this presentation. Except as required by law, Aadi undertakes no obligation to revise or update any forward-looking statement, whether as a result of new information, future events or otherwise.

2

Our Vision

To make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers

3

Aadi Bioscience is Unlocking the Power of mTOR Inhibition

Sources: 1) AFINITOR prescribing information; 2) TORISEL prescribing information; 3) Hou et al., AACR Molecular Targets 2021 (Abstr P138); 4) ZORTRESS prescribing information; 5) RAPAMUNE prescribing information

4

Established Company Building on Commercial and Clinical Success

Commercial backbone with successful launch of FYARRO®

• Treatment for advanced malignant PEComa
• $45M in sales achieved since launch*
• Continued, steady demand

Advanced pipeline targeting multiple types of mTOR-driven tumors with 2024 milestones

• PRECISION1 registration-intended tumor agnostic trial in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations ongoing, expected completion by year-end
• Phase 2 trials in endometrioid-type endometrial carcinoma and neuroendocrine tumors ongoing, initial data expected in 2024

Accomplished leadership with deep expertise and responsible capital management

* Commercial launch on Feb 22, 2022. Sales as of close of 1Q 2024.

5

Boldly Combining nab Technology and Therapies to Address Two Categories of mTOR-dependent Tumors

Sources: 1) Lee, et. Al., (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence, Expert Opinion

on Pharmacotherapy, 19:8, 909-928, 2) Soliman PT et. Al., (2020) Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-

• Center, Single Arm, Phase II Study. Clin Cancer Res. Feb 1;26(3):581-587. 3) Slomovitz BM, et al. Gynecol. Oncol. 2022;164:481-491.

Advancing Our Pipeline to Deliver New Breakthroughs

Evaluation of additional new single agent and combination trials ongoing

7

FYARRO® First Approved Indication: Advanced Malignant PEComa

FYARRO in Malignant PEComa: Continuing Product Demand

10 * Commercial launch on Feb 22, 2022. Sales as of close of 1Q 2024.